NHS to Offer Weight-Loss Jab Wegovy for Heart Attack and Stroke Prevention
The National Institute for Health and Care Excellence (NICE) has sanctioned the use of Wegovy, a weekly weight-loss injection, for over one million people in England identified as being at elevated risk of heart attacks and strokes. This initiative extends to individuals with existing cardiovascular conditions or serious peripheral arterial disease who are also overweight.
Enhanced Protection for Vulnerable Patients
Patients already receiving heart medications, such as statins, will be assessed by a GP or specialist to determine the suitability of Wegovy as part of a comprehensive treatment plan that includes a healthy diet. Clinical trials involving tens of thousands of participants demonstrated that the jab, when used alongside existing heart medicines, reduced the risk of future heart attacks and strokes by 20%. Notably, these benefits emerged early in the trials, suggesting the drug's direct impact on the heart and blood vessels, beyond mere weight loss.
Helen Knight from NICE emphasised the compelling evidence, stating, "The evidence from the clinical trial is compelling. It showed that people taking semaglutide alongside their existing heart medicines were significantly less likely to have another heart attack or stroke."
Administration and Eligibility
Patients prescribed Wegovy will self-administer the drug at home using a pen injector device. It is recommended for individuals with a Body Mass Index (BMI) of 27 or higher, classifying them as overweight or obese. The rollout is anticipated to commence this summer. While the drug, also known as semaglutide, works by suppressing appetite and slowing digestion, potential side effects include bloating, nausea, and discomfort.
NICE has secured a cost-effective agreement with the manufacturer, Novo Nordisk. However, treatment is currently limited to two years on the NHS, with ongoing studies into its long-term risks and benefits, particularly concerning potential muscle mass reduction.
